StockTake: Neurizon’s lead asset shows positive results in latest study
Neurizon Therapeutics’ (ASX:NUZ) lead drug candidate has demonstrated positive results in the latest round of testing with Tessara Therapeutics.
NUZ-001 has shown it promotes healthy and viable brain tissues, potentially demonstrating its use to provide short-term treatment for further neurodegenerative diseases.
Watch the video to hear more.
This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.
This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Related Topics

SUBSCRIBE
Get the latest breaking news and stocks straight to your inbox.
It's free. Unsubscribe whenever you want.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.